Aardvark Therapeutics, Inc.
AARD
$4.18
-$0.36-7.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.90M | 4.41M | 3.97M | 2.70M | 2.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.46M | 18.70M | 17.70M | 15.85M | 10.47M |
| Operating Income | -22.46M | -18.70M | -17.70M | -15.85M | -10.47M |
| Income Before Tax | -21.59M | -17.60M | -16.32M | -14.37M | -9.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.59M | -17.60M | -16.32M | -14.37M | -9.31M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.59M | -17.60M | -16.32M | -14.37M | -9.31M |
| EBIT | -22.46M | -18.70M | -17.70M | -15.85M | -10.47M |
| EBITDA | -22.45M | -18.69M | -17.69M | -15.84M | -10.47M |
| EPS Basic | -0.99 | -0.81 | -0.75 | -0.66 | -0.71 |
| Normalized Basic EPS | -0.62 | -0.50 | -0.47 | -0.41 | -0.44 |
| EPS Diluted | -0.99 | -0.81 | -0.75 | -0.66 | -0.71 |
| Normalized Diluted EPS | -0.62 | -0.50 | -0.47 | -0.41 | -0.44 |
| Average Basic Shares Outstanding | 21.82M | 21.78M | 21.71M | 21.69M | 13.19M |
| Average Diluted Shares Outstanding | 21.82M | 21.78M | 21.71M | 21.69M | 13.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |